Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis

Quenet, Sara; Laporte, Silvy; Décousus, Hervé; Leizorovicz, Alain; Epinat, Magali; Mismetti, Patrick

doi:10.1016/s0741-5214(03)00607-4

Cited by 80 publications

(55 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,9 An increased risk of DVT/PE in men with SVT has been described in the POST study 4 and in the Superficial Thrombophlebitis Treated by Enoxaparin Study Group trial. 23 The higher risk in men than in women of recurrent VTE has been recognized for some time, 24 but only recently has it become clear that this disparity in risk also exists for first events. 25 Although the cause of the risk difference between the genders is not yet known, our results are in line with these findings.…”

Section: Discussionmentioning

confidence: 99%

Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study

Cannegieter

Horváth‐Puhó

Schmidt

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• In the 3 months after isolated SVT, the risk of a deep venous event or pulmonary embolism is 3.4%.• This risk remains fivefold increased more than 5 years after the superficial event.Recently, it has become apparent that superficial vein thrombosis (SVT) can have serious complications. However, the magnitude of the risk of subsequent deep venous and arterial thrombotic events remains unknown. We examined this in a nationwide population-based setting during a period when SVT was not treated routinely with anticoagulants. The Danish National Registry of Patients, covering all Danish hospitals, was used to identify 10 973 patients with a first-time diagnosis of SVT between 1980 and 2012. A comparison cohort of 515 067 subjects, matched by age, gender, and calendar year, was selected from the general Danish population. Outcomes were venous thromboembolism, acute myocardial infarction, ischemic stroke, and death. During median follow-up of 7 years, the incidence rate of venous thromboembolism was 18.0/1000 person-years (95% confidence interval [CI], 17.2-18.9). The highest risk occurred in the first 3 months (3.4%; 95% CI, 3.0-3.7). Compared with the general population, the hazard ratio was 71.4 (95% CI, 60.2-84.7) in this period, steadily decreasing to 5.1 (95% CI 4.6-5.5), 5 years after the SVT. The hazard ratios for acute myocardial infarction, stroke, and death were 1.2 (95% CI, 1.1-1.3), 1.3 (95% CI, 1.2-1.4), and 1.3 (95% CI, 1.2-1.3), respectively, with the highest risk also shortly after SVT. These data indicate the prognostic importance of SVT and may form the basis for clinical decisionmaking regarding anticoagulation. (Blood. 2015;125(2):229-235)

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study

Cannegieter

Horváth‐Puhó

Schmidt

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

“…Comparison between patients treated with anticoagulants and those left untreated Of all followed-up patients, 16.2% (n = 173) did not receive any anticoagulant treatment. History of recent surgery was more prevalent in this group of patients than among those treated with anticoagulant drugs (8% vs. 4%, P = 0.03).…”

Section: Three-month Adverse Outcomesmentioning

confidence: 99%

Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies

Galanaud

Bosson

Genty

et al. 2012

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary. Background: The management strategies for symptomatic isolated superficial vein thrombosis (SVT) (without concomitant deep vein thrombosis [DVT] or pulmonary embolism [PE]) have yet to achieve widespread consensus. Concerns have been raised regarding the usefulness of prescribing anticoagulant treatments to all patients with isolated SVT. Determining the isolated SVT subgroups who have the highest risks of venous thromboembolism (VTE) recurrence (composite of DVT, PE, and new SVT) may facilitate the identification of patients who are likely to benefit from anticoagulant treatment. Design and methods: We performed a pooled analysis on individual data from two observational, multicenter, prospective studies, to determine predictors for VTE recurrence and their impact in an unselected population of symptomatic isolated SVT patients. Results: One thousand and seventy‐four cases of symptomatic isolated SVT were followed up at 3 months. VTE recurrence was observed in 3.9% of the patients; 16.2% of the patients did not receive anticoagulants, and 0.6% experienced a VTE recurrence. Cancer, personal history of VTE and saphenofemoral/popliteal involvement significantly increased the risk of subsequent VTE or DVT/PE in univariate analyses. Only male sex significantly increased the risk of VTE or DVT/PE recurrence in multivariate analyses. Twelve per cent of the patients had cancer or saphenofemoral junction involvement, and were at higher risk of DVT/PE recurrence than patients without those characteristics (4.7% vs. 1.9%, P = 0.06). Conclusions: In patients with symptomatic SVT, only male sex significantly and independently increased the risk of VTE recurrence. Cancer or saphenofemoral junction involvement defined a population at high risk for deep VTE recurrence. Some SVTs might be safely managed without anticoagulants.

show abstract

“…1) Patients with superficial thrombophlebitis should be screened for hypercoagulability because of their high prevalence of hypercoagulable states caused by a deficiency in antithrombin III or abnormalities in protein C and S. 1,13) Male gender, history of thromboembolism, severe venous insufficiency, and shorter interval between symptom onset and diagnosis (less than 7 days) are also reported to be risk factors associated with complications after superficial vein thrombosis. 12) In this study, Protein C deficiency, hormone therapy, malignancy, and driving as an occupation were found to increase the risk of thrombosis. Preventing venous thrombosis occurrence is needed for all patients with risk factors, including those listed above as a matter of course.…”

Section: Discussionmentioning

confidence: 69%

“…1,[8][9][10][11][12] With one exception (case 12 with lung cancer), all patients in this study underwent surgery to prevent extension of the saphenous thrombus to a deep vein. Four cases underwent surgery after anticoagulation therapy.…”

Section: Discussionmentioning

confidence: 99%

Clinical Features and Developing Risks of Saphenous Vein Thrombophlebitis

Rikimaru¹

2016

Annals of Vascular Diseases

View full text Add to dashboard Cite

Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis

Cited by 80 publications

References 19 publications

Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study

Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study

Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies

Clinical Features and Developing Risks of Saphenous Vein Thrombophlebitis

Contact Info

Product

Resources

About